The formulation of the present invention utilises albutarol, a beta-2 receptor agonist, more popularly known as salbutamol as one of the main active ingredient. Other preferred active ingredient of the topical formulation include citrate, particularly its acid, and niacin, more preferably, nicotinic acid. Still other preferred ingredients are pentoxyphyllin and dipyridamole. Several inert base substances are also added. These are helpful in maintaining the active components in a state that ensures dermal permeability, sustained action and integrity of the ointment. The base materials include paraffins, alcohols, a surfactant, a hygroscopic agent and some perfume. The preferred solvent of the base materials is refined water, making the formulation an oil-in-water emulsion preparation.
